Sunovion Submits New Drug Application to the FDA for Apomorphine Sublingual Film for the Treatment of OFF Episodes Associated with PD

(March 30, 2018) – Sunovion Pharmaceuticals Inc. today announced that it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) on March 29, 2018, for apomorphine sublingual film (APL-130277) to treat motor fluctuations (OFF episodes) experienced by people living with Parkinson’s disease (PD). Read more…